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REVIEW
Abstract: Hemoglobin (Hb) released during hemolysis is a potent oxidant. Extracorpuscular
Hb may enter the vessel wall and mediate low-density lipoprotein oxidation, thereby promoting
the development and progression of atherosclerosis. Haptoglobin (Hp) is an antioxidant protein
as a result of its ability to bind Hb and block Hb-induced oxidative damage. Hp also facilitates
the removal of Hb from the extravascular compartment via the CD163 macrophage scavenger
receptor. In man, there are two common alleles for Hp denoted 1 and 2, and correspondingly,
three different possible genotypes: Hp1-1, Hp2-1, and Hp2-2. We have recently demonstrated
in several longitudinal studies that Hp genotype is an independent risk factor for diabetic
vascular complications. Specifically, we have shown that diabetic individuals with Hp 2-2 are
more likely to develop nephropathy, retinopathy, and cardiovascular disease as compared with
those with Hp2-1 or Hp1-1. Mechanistically, we have found significant Hp type differences in
the antioxidant and CD163-mediated scavenging and activation functions of the different Hp
protein types. Furthermore, we have demonstrated that these functions are modified in the
diabetic state. In this review, we focus on the clinical studies associating the Hp polymorphism
and diabetic vascular complications, and the molecular basis behind this interaction.
Keywords: diabetes, cardiovascular disease, haptoglobin polymorphism, hemoglobin,
oxidative stress
Introduction
The overwhelming public health burden of diabetes mellitus (DM) is due in large
part to the development of late vascular complications. The most prevalent of these
complications is atherosclerotic cardiovascular disease (CVD). The percentage of
total deaths from CVD in type 1 and type 2 diabetes has progressively increased so
that more than 75% of all deaths among diabetics are directly attributable to CVD
(Bierman 1992; Grundy et al 1999). Approximately 35% of diabetes type 1 patients
die from CVD before the age of 55 (Krolewski et al 1987). Prospective epidemiologic
studies of individuals at risk for CVD yield consistent temporal relationships between
diabetes and both incident CVD and mortality (Resnick and Howard 2002). Diabetes
increases the risk of CVD 2- to 5-fold compared with the general population (Kannal
and McGee 1979; Stamler et al 1993; Howard et al 1999). The overall prevalence of
CVD is over 55% in adults with diabetes as compared with 2%–4% of the general
population. The rate of cardiovascular mortality is more than doubled in men and
more than quadrupled in women with diabetes compared with nondiabetic individuals
(Carroza et al 1993).
In addition to independent risk factors for CVD attributable to the diabetic state,
such as insulin resistance, hyperinsulinemia, and hyperglycemia, several other known
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risk factors for CVD are more common in diabetics than
the general population. These comorbid risk factors
frequently associated with diabetes include hypertension,
central obesity, dyslipidemia, family history of CVD,
endothelial dysfunction, and coagulation abnormalities
(Haydan and Reaven 2000; Sowers et al 2001). The
development of diabetic vascular complications is related
to age of onset of hyperglycemia, the duration of the disease,
and the degree of glycemic control. Intensive therapy aiming
to maintain blood glucose levels close to the normal range
has been shown to effectively delay the onset and slow the
progression of diabetic vascular complications (The
Diabetes Control and Complications Trial Research Group
1993). However, the contribution of hyperglycemia and all
conventionally measured risk factors together can account
for no more than 25% of the excess CVD risk in diabetes
(Pyorala et al 1987). Moreover, a significant percentage of
diabetics have been shown to be resistant to the develop-
ment of vascular complications in spite of poor glycemic
control.
There exists a growing body of evidence that diabetic
vascular disease develops only in those patients who are
genetically susceptible (Chowdhury et al 1995, 1999;
Parving et al 1996; Ruiz 1997; Marre 1999). Hyperglycemia
appears to be a necessary but not sufficient condition for
the development of diabetic vascular disease. Family studies
have supported the hypothesis of a genetic predisposition
for diabetic complications by demonstrating a familial
clustering of diabetic nephropathy and CVD. Additionally,
it has been demonstrated that there exist significant ethnic
differences in the incidence of CVD in subjects with diabetes
that could not be explained by differences in conventional
cardiovascular risk factors between these ethnic groups (UK
Prospective Diabetes Study Group 1998). Analysis of
population groups, such as the Pima Indians, has shown
markedly higher rates of diabetic retinopathy and
nephropathy than would be expected based on the known
risk factors (Imperatore et al 1998). Various candidate genes
with known functional polymorphisms have been examined
regarding their ability to demonstrate an association between
CVD and diabetes, including the genes for paraxonase,
angiotensin-converting enzyme, glutathione peroxidase, and
superoxide dismutase (Ruiz et al 1995; Tarnow et al 2000).
We have recently demonstrated in several prospective and
cross-sectional population studies that a polymorphism in
the haptoglobin (Hp) gene is an independent risk factor for
diabetic vascular disease.
Haptoglobin polymorphism
Hp is a Hb-binding serum protein. It is an acute phase protein
synthesized mainly in the liver and found at levels of
30–300 mg/dL in normal human serum (Katnik and Jadach
1996). Hp serum levels are increased up to 3- to 8-fold
during the acute phase reaction and in response to injury
(Dobryszycka 1997). The hepatic synthesis of Hp is induced
by interleukin-6 (IL-6), IL-1 and tumor necrosis factor-α
(TNF-α). Hp is also expressed in specific nonhepatic cells,
including adipocytes and lung cells, and its levels are
increased after inflammation similar to that observed in
hepatocytes (Kalmovarin et al 1991). Moreover, Hp is highly
expressed in arteries after sustained flow changes induced
by shear stress and nitric oxide, which influence IL-6
expression. Arterial Hp is believed to play a role in cell
migration and arterial restructuring (Smeets et al 2002).
In man, there are two alleles for Hp, denoted 1 and 2,
giving rise to three major phenotypes. Individuals
homozygous for the 1 allele express the Hp1-1 phenotype
at the protein level. Individuals homozygous for the 2 allele
express the Hp2-2 phenotype, whereas heterozygotes
express the Hp2-1 phenotype. The Hp gene locus on
chromosome 16q22 consists of 5 exons encoding the 1 allele,
or 7 exons encoding the 2 allele. The two alleles appear to
have been generated from the 1 allele by an intragenic
duplication of exons 3 and 4, presumably by a non-
homologous DNA crossing-over event (Maeda et al 1984).
Hp is synthesized as a single chain which is cleaved to an
amino-terminal α-chain and a carboxy-terminal β-chain,
linked by disulfide bonds (Raugei et al 1983). The β-chain
is identical in both Hp alleles, while the α-chains differ.
The α-chain of the Hp1 allele binds one β-chain and one
other α-chain, both by disulfide bonds. Therefore, subjects
with the Hp1-1 genotype produce a single (αβ)2 homodimer
with a molecular weight of 86 KDa. As the cysteine forming
the intermolecular disulfide bond between the α-chains is
duplicated in the 2 allele, human’s homozygotes for the 2
allele (Hp2-2) have multimeric cyclic haptoglobin molecules
with a molecular weight of 170–900 KDa. Individuals with
the Hp2-1 genotype demonstrate a variety of linear
homodimers and multimers with a molecular weight of
86–300 KDa. Each β-chain of Hp binds an αβ-dimer of Hb
to form the Hp-Hb complex (Wejman et al 1984) (Figure 1).
Hp protein phenotypes are easily distinguished by
nondenaturing gel electrophoresis of Hb-enriched serum.
The Hp-Hb complex in the gel is identified by virtue of its
peroxidase activity, and each Hp type gives rise to a signatureVascular Health and Risk Management 2005:1(1) 21
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banding pattern. The Hp type can also be determined from
DNA by PCR (Koch et al 2002), and there exists complete
correspondence between the Hp type assigned by the two
methods. There exist marked geographic differences in the
distribution of the Hp phenotype in different populations.
The highest incidence of the Hp1 allele has been reported
in Africa and South America (up to 92% in Mexican
Lacandon), and the lowest in Southeast Asia (minimum 7%
in Indian Irulas) (Langlois and Delanghe 1996). There are
no differences in frequency of the two Hp alleles in diabetics
and nondiabetics in any given population.
Haptoglobin function
The best known function of Hp is to bind free Hb released
into the plasma to form a stable Hp-Hb complex. The two
proteins form a complex with extremely high affinity (KD
estimated to be greater than 10
–15 M) (Hwang and Greer
1980; McCormick and Atassi 1990).
Intravascular hemolysis is a physiological phenomenon
but may be increased in certain pathological conditions.
Normally, senescent erythrocytes approaching the end of
their 120-day lifespan are degraded in the spleen, liver, or
bone marrow, but about 10% of red cell breakdown (about
650 mg per day or about 27 mg per hour) occurs within blood
vessels (Garby and Noyes 1959). Free Hb in the circulation
passes through the glomeruler filter resulting in renal
damage. Furthermore, free Hb is involved in a variety of
toxic side effects. Free Hb is considered as an extremely
potent pro-oxidant agent and can catalyze various oxidative
and peroxidative reactions, such as the Fenton reaction
resulting in the generation of hydroxyl radical (Everse and
Hsia 1997). Hp plays an essential role in capturing free Hb,
thus preventing its deposition in the glomeruli and proximal
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Figure 1 Subunit organization of Hp. The Hp1 monomer can bind just one other monomer to form a homodimer in Hp1-1 individuals or as one of the different
possible complexes in Hp2-1 individuals. Hp2 monomer can bind two monomers to form a variety of cyclic multimers in Hp2-2 or a variety of linear complexes in
Hp2-1 individuals. In the Hp-Hb complex, each β subunit of the Hp monomer binds an αβ-dimer of Hb.Vascular Health and Risk Management 2005:1(1) 22
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tubule cells of the kidney. Moreover, Hp functions as an
antioxidant through its ability to bind Hb and thereby
preventing oxidative tissue damage mediated by free Hb. In
vitro, Hp has been demonstrated to inhibit Hb-induced
linolenic acid and low-density lipoprotein (LDL) oxidation
(Gutteridge 1987; Miller et al 1997). Hp knockout mice are
more prone to oxidative tissue damage (such as renal damage
and endothelial dysfunction) and mortality following
hemolysis, demonstrating the importance of Hp in the
physiological defense against Hb toxicity (Lim et al 1998).
Most of the Hp-Hb complexes (90%) are taken up by
hepatocytes through a poorly characterized transmembrane
receptor. Recently, a specific high-affinity scavenger
receptor for the Hp-Hb complex has been identified
exclusively on monocytes and macrophages (Kristiansen et
al 2001). This specific receptor-ligand interaction leads to
uptake of Hp-Hb complexes from plasma as well as from
injured or inflammated tissues (such as the vessel wall)
within which free Hb may sieve. The specific binding of
the Hp-Hb complex to CD163 leads to endocytosis and
degradation of the complex inside the lysosome. Hb
degradation leads to globin proteolysis and globin-derived
heme conversion to iron and bilirubin (Gravensen et al
2002).
CD163 is present on the surface of 15%–30% of freshly
isolated monocytes and virtually all macrophages (Hogger
et al 1998). The expression of CD163 is significantly
increased in the late phase of the inflammatory process
(Zwadlo et al 1987). CD163 expression is upregulated in
response to antiinflammatory factors, such as gluco-
corticoids and IL-10 and in response to proinflammatory
cytokines such as IL-6 and GM-CSF. Its expression is down-
regulated by proinflammatory cytokines, such as
lipopolysacharide, interferon-γ (INF-γ), and TNF-α
(Buechler et al 2000).
Cross-linking of CD163 expressed on macrophages with
monoclonal antibody has been shown to produce a protein
tyrosine kinase-dependent signal that leads to secretion of
proinflammatory cytokines such as IL1-β, IL-6, and GM-
CSF (Van Den Heuvel et al 1999). Moreover, CD163
receptor contributes to the adhesion of monocytes to
activated endothelial cells (Wenzel et al 1996). On the other
hand, Philippidis et al have shown that CD163 activation is
linked to antiinflammatory effector pathways. They have
demonstrated that Hp-Hb complex, bound to CD163,
triggers IL-10 release and heme oxygenase-1 protein
induction in human macrophages in vitro and in tissue
macrophages ex vivo (Philippidis et al 2004).
There exists considerable in vitro and in vivo data
supporting differences in the antioxidant, scavenging, and
immunomodulatory properties between the different Hp
types. Individuals with the Hp2-2 phenotype have been
found to have significantly lower levels of serum vitamin C
(Langlois et al 1997), higher serum iron, and higher
circulating oxidized LDL (oxLDL)/LDL ratios compared
with those with the Hp2-1 or the Hp1-1 type (Delanghe and
Langlois et al 2002; Brouwers et al 2004). In our laboratory,
we have demonstrated that there are functional differences
in the antioxidant capacity of the different Hp types towards
Hb-driven oxidation of linolenic acid and LDL (Melamed-
Frank et al 2001). Regarding the Hp-Hb complex CD163
interaction, we and others have demonstrated several
differences between Hp1-1-Hb and Hp2-2-Hb complexes.
First, Hp2-2-Hb complexes exhibit a 10-fold higher affinity
to CD163 compared with the Hp1-1-Hb complexes. Second,
we have recently found that the rate of clearance of the Hp1-
1-Hb by CD163 is markedly greater than that of Hp2-2-Hb.
Third, we have shown that Hp2-2-Hb complex is superior
to Hp1-1-Hb complex in activating the CD163 receptor and
results in more inositol tri-phosphate (IP3) production and
greater intracellular calcium mobilization (Asleh et al 2003).
Finally, Philippidis et al (2004) have recently demonstrated
that Hp1-1-Hb complexes result in a greater production of
the antiinflammatory cytokine IL-10 as compared with Hp2-
2-Hb complexes.
Clinical studies in humans
associating Hp phenotype and
diabetic vascular disease
Several reports from our laboratory have established a strong
association between the Hp phenotype and diabetic vascular
complications. Hp1-1 confers significant protection,
Hp2-1 confers partial protection, and Hp2-2 can be regarded
as a major risk factor for vascular complications in diabetics.
Nephropathy, retinopathy, and
restenosis after angioplasty
Our initial studies with the Hp polymorphism and diabetic
complications were from three cross-sectional studies done
in Israel. We demonstrated that the Hp1-1 phenotype was
associated with a marked decrease in the prevalence ofVascular Health and Risk Management 2005:1(1) 23
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diabetic nephropathy (DN), diabetic retinopathy (DR), and
restenosis after percutaneous transluminal coronary
angioplasty (PTCA).
Diabetic nephropathy
This study included 110 consecutive normotensive type 1
and type 2 diabetics. The difference in the incidence of DN
between patients with the three Hp phenotypes was
statistically significant for type 1 diabetic patients and for
all diabetic patients combined. Of the 54 type 1 diabetics,
13 demonstrated DN. None (0/13) of the patients with
Hp1-1 phenotype had DN, whereas 5 of 22 (23%) with
Hp2-1 and 8 of 21 (38%) with Hp2-2 had evidence of DN
(p < 0.04). For both types of diabetes combined, none (0/18)
of the Hp1-1 patients showed any sign of nephropathy, as
compared with 10 of 37 (27%) with Hp2-1 and 19 of 55
(34%) with Hp2-2 (p < 0.02).
There were 15 patients with macroalbuminuria in this
study. The risk of developing macroalbuminuria was found
to be significantly correlated with Hp phenotype for both
types of diabetes combined. None (0/18) of the Hp1-1
patients had macroalbuminuria, whereas 3 of 37 (8%)
patients with the Hp2-1 and 12 of 55 (22%) of the patients
with Hp2-2 had macroalbuminuria (p < 0.03). This study
demonstrated a graded-risk correlation between presence,
as well as severity, of DN and Hp phenotype (Levy et al
2000; Nakhoul et al 2001).
Diabetic retinopathy
This study included 52 consecutive patients with type 1
diabetes, of which 25 had evidence of DR. There was
significantly lower prevalence of DR in patients with the
Hp1-1 compared with patients with the Hp2-1 and Hp2-2
phenotypes. Only 1 of 12 patients (8%) with Hp1-1
phenotype had DR, whereas 12 of 20 (60%) with Hp2-1
and 12 of 20 patients (60%) with Hp2-2 had evidence of
DR (p < 0.002). This demonstrated that Hp1-1 diabetics are
provided with increased protection against the development
of DR compared with the other Hp phenotypes (Nakhoul et
al 2000).
Restenosis after PTCA
Three studies investigating the relationship between the Hp
type and restenosis have been reported (Roguin et al 2001,
2002, 2003). In two of these studies (Roguin et al 2001,
2002) we found a significantly reduced incidence of
restenosis in Hp1-1 diabetic individuals, while the third
study (Roguin et al 2003) failed to demonstrate any
difference in the incidence of restenosis as a function of
Hp type.
Cardiovascular disease
We have established in four independent prospective
longitudinal studies and 1 large cross-sectional population
study that Hp genotype is an independent risk factor for
CVD and that this relationship is specific for DM. Taken
together these five studies suggest that Hp genotype may
be useful in predicting which patients with diabetes will
develop CVD.
Strong Heart Study
The goal of this study was to determine if the Hp phenotype
was predictive of CVD in diabetes. The Strong Heart Study
(SHS) was a population-based longitudinal study of CVD
in American Indians. We analyzed the Hp phenotype in a
matched case-control study of stored serum samples from
the SHS. In multivariate analyses controlling for
conventional CVD risk factors and DM characteristics, Hp
phenotype was a highly statistically significant predictor of
CVD in DM (Table 1). The odds ratio of having CVD in
DM with the haptoglobin phenotype 2-2 was 5 times greater
than that in DM with the Hp1-1 phenotype (p = 0.002). An
intermediate risk of CVD was associated with the Hp2-1
phenotype. No significant association between Hp type
and CVD risk was found in nondiabetic individuals
(Levy et al 2002).
Table 1 Relative risk of incident CVD according to DM status
and Hp type in the Strong Heart Study adjusted for all CVD
risk factors and DM characteristics
Variable OR 95% CI p-value
DM and Hp 2-1 (vs DM and Hp 1-1) 1.63 0.74–3.63 0.228
DM and Hp 2-2 (vs DM and Hp 1-1) 4.96 1.85–13.33 0.002
DM and Hp 2-2 (vs DM and Hp 2-1) 3.04 1.30–7.09 0.010
No DM, Hp 2-1 (vs no DM, Hp 1-1) 1.46 0.44–4.87 0.542
No DM, Hp 2-2 (vs no DM, Hp 1-1) 2.73 0.81–9.26 0.107
No DM, Hp 2-2 (vs no DM, Hp 2-1) 1.88 0.73–4.80 0.190
Source: Data adapted from Levy et al (2002).
Abbreviations: CVD, cardiovascular disease; DM, diabetes mellitus; Hp,
haptoglobin; OR, odds ratio; CI, confidence interval.Vascular Health and Risk Management 2005:1(1) 24
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Munich Stent Study
The goal of this study was to determine if the Hp genotype
was predictive of major adverse cardiac events after coronary
artery stenting in individuals with diabetes. A consecutive
series of 935 treated (oral agents and/or insulin) diabetic
patients were followed for 1 year after stenting for major
adverse cardiac events (MACE) defined as target vessel
revascularization (TVR), myocardial infarction (MI), and
death. In multivariate analysis controlling for all known
determinants of outcome after stent placement we found
that Hp genotype was a highly significant independent
predictor of major adverse cardiac events in the 1-year period
following stent placement in individuals with diabetes. We
found significant differences in the risk of developing MI
and in the need for TVR in the 1-year period following stent
placement (Roguin et al 2003) (Table 2).
Acute myocardial infarction
The goal of this study was to determine if the Hp phenotype
was predictive of MI size and adverse cardiac events in the
peri-infarct period in patients with DM. Hp phenotype was
determined in a consecutive series of over 620 individuals
presenting with acute MI to the coronary intensive care unit
(224 with DM) of the Rambam Medical Center in Haifa,
Israel. Major adverse cardiac events (death, reinfarction, and
revascularization) were prospectively identified occurring
within 30 days. MI size and the severity of left ventricular
dysfunction were assessed by peak creatine kinase, ECHO,
and Killup score. We found a significant interaction effect
between Hp type and diabetes in predicting mortality and
major adverse cardiac events at 30 days. Specifically, the
mortality rate in DM Hp1-1 patients was significantly less
than in DM patients with the Hp2 allele, but there was no
difference between the Hp types in these outcomes in
nondiabetic individuals. For the combined MACE end point
the relative risk was 5 times greater in diabetic Hp2-2
individuals as compared with diabetic Hp1-1 individuals
(p < 0.0001) (Table 3). There was no difference in mortality
or in the combined endpoint according to Hp type in
nondiabetic patients. Diabetic patients with Hp1-1 also had
significantly smaller and less severe myocardial infarctions
as compared with diabetic patients with Hp2-1 or Hp2-2
(Suleiman et al 2003).
HOPE (Heart outcomes prevention evaluation)
The HOPE study evaluated the effects of daily
administration of 400 IU of vitamin E and/or ramipril for
4.5 years on the development of MI, stroke, and
cardiovascular death in people with CVD or diabetes plus 1
other risk factor (Yusuf et al 2000). In diabetic patients
receiving double placebo (no ramipril or vitamin E), Hp
phenotype was a significant predictor of the primary
composite outcome (Hp1-1 20.8%, Hp2-1 16.4 %, Hp2-2
31.9%, p = 0.03). The effect of antioxidants on this risk will
be discussed below.
Framingham Offspring Cohort
We sought to examine the relationship between Hp type,
diabetes status, and coronary artery disease in a cross-
sectional analysis of a large community-based cohort from
the Framingham Heart Offspring Study (Kannel and McGee
1979). We determined the Hp phenotype in over 3200
participants of the study who attended the seventh
examination of the study. This study therefore examined
CVD prevalence (since this was a cross-sectional study)
rather than incidence of CVD in individuals with and without
diabetes segregated by Hp type. We demonstrated that there
was a significant difference in the nature of association
between Hp type and CVD in individuals with diabetes and
those without diabetes (p = 0.01 for interaction term of Hp
type and diabetes) (Levy et al 2004).
Table 2 Incidence of major adverse cardiac events in the one
year follow-up of 935 consecutive diabetic patients undergoing
coronary artery stent placement
Hp 1-1 Hp 2-1 Hp 2-2 p
n 129 424 382
Death 7 (5.4%) 28 (6.6%) 15 (3.9%) 0.22
Acute MI 0 (0%) 20 (4.7%) 32 (8.4%) < 0.0001
TVR 21 (16.3%) 82 (19.3%) 91 (23.8%) 0.040
MACE 27 (20.9%) 112 (26.4%) 120 (31.4%) 0.015
Source: Data adapted from Roguin et al (2003).
Abbreviations: MI, myocardial infarction; TVR, target vessel revascularization;
MACE, major adverse cardiac events.
Table 3 Incidence of major adverse cardiac events at 30 days
in 224 consecutive diabetic patients presenting with myocardial
infarction
Hp 1-1 Hp 2-1 Hp 2-2 p-value
n 28 83 113
Death 0 19 (23%) 28 (25%) 0.01
Re-infarction 0 2 (2%) 6 (5%) 0.31
Revascularization 3 (11%) 23 (28%) 35 (31%) 0.09
Composite 3 (11%) 42 (51%) 62 (55%) < 0.0001
Source: Data adapted from Suleiman et al (2003).Vascular Health and Risk Management 2005:1(1) 25
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Molecular basis for the interaction
between the Hp phenotype and
diabetic CVD
The clinical studies reported above demonstrated that the
polymorphism in the Hp gene is an independent risk factor
for the development of CVD in individuals with diabetes.
No relationship was found between the Hp type and the
risk for CVD in the nondiabetic population. We have sought
to understand the molecular mechanism whereby the Hp
polymorphism confers different susceptibility to CVD and
the reason this interaction is specific for the diabetic state.
A substantial body of evidence supports the hypothesis
that oxidative modification of LDL or other oxidative events
within the blood vessel wall, promotes the development and
progression of atherosclerotic lesions leading to CVD.
Among several molecular components that function as active
catalyzers of LDL oxidation, free Hb is a potent oxidant of
LDL by the Fenton reaction (Gutteridge 1987; Bamm et al
2003). As Hb concentration in the red cells is in the
millimolar range, a minimal cell rupture suffices to achieve
local micromolar concentrations of free Hb. At sites of
endothelial injury, Hb may sieve into the subendothelial
space catalyzing the oxidation of LDL. Fernandez and
colleagues (2001) have shown that intravascular hemolysis
increases oxidative stress and atherogenicity of diet-induced
hypercholesterolemia in rabbits. In the diabetic condition,
the erythrocyte membrane demonstrates structural and
functional modifications, resulting in a reduced lifespan and
an increase in its turnover (Venerando et al 2002).
Furthermore, diabetes is associated with accelerated
endothelial cell dysfunction and injury (Laight et al 1999),
thus the amount of Hb penetrating into the blood vessel
wall may be significantly increased. Hp, which is found in
more than 400 molar excess compared with free Hb, can
bind rapidly free intravascular Hb released in the circulation
and prevent Hb-driven oxidation. However, this may not be
true within the vessel wall where Hp is not normally found.
The antioxidant function of Hp appears to be inhibited
in the diabetic state. We have recently demonstrated that
the oxidation of LDL mediated by glycosylated Hb (GlyHb),
a fraction that is markedly increased in diabetes, is not
completely blocked by the binding of Hp. Therefore, unlike
the Hp-Hb complex, the GlyHb-Hp complex is a potent
potential oxidant of LDL within the vessel wall. It is critical
in the diabetic state, where there is an increase in hemolysis,
GlyHb concentration and endothelial injury, to capture and
clear Hb-Hp complexes from the subendothelial space as
rapidly as possible to minimize their oxidative potential and
the atherogenic damage that they may cause. Indeed as
discussed above we have shown that Hp1-1-Hb complexes
are more rapidly scavenged as compared with the Hp2-2-
Hb complexes. We have therefore proposed that the
interaction between these processes results in significantly
less oxidative damage within the vessel wall in diabetic
individuals with Hp1-1 phenotype compared with those with
Hp2-2 phenotype (Asleh et al 2003).
Several additional mechanisms have been identified that
may be important in understanding the differential
susceptibility to CVD in diabetic subjects with the different
Hp types. First, the Hp polymers present in individuals with
1-1, 2-1, or 2-2 phenotypes differ dramatically in their shape
and size. These differences confer differential sieving
potential to enter the subendothelial space, where Hp is
needed in order to neutralize the harmful oxidizing effect
of free Hb that may be released at sites of vascular injury.
Second, recent studies have highlighted the role of immune
cells and inflammatory mediators in the initiation, growth,
and rupture of atherosclerotic plaques (Greaves and
Channon 2002). We have demonstrated marked differences
between the two Hp types (Hp2-2 is more potent than
Hp1-1) in two distinct markers of macrophage activation
via CD163 receptor. We propose that these differences in
cell activation may result in high production of inflammatory
mediators implicated in atherosclerosis. Third, we found a
profound and significant reduction in the percentage of
monocytes expressing the surface CD163 in patients with
diabetes, resulting in a decrease in the ability to scavenge
the Hp-Hb complex in the diabetic state (Asleh et al 2003).
Recently, we have demonstrated a correlation between
Hp phenotype and the amount of catalytically active redox
active iron in the diabetic state. Iron has been hypothesized
to be of significant importance in morbidity and mortality
from atherosclerotic CVD, due to its strong oxidative activity
by the Fenton reaction (Sullivan 1981; Fu et al 1998). It has
been shown that iron induces cellular lipid peroxidation in
macrophages, thus increasing cell-mediated LDL oxidation
(Fuhrman et al 1994). Over 99% of the iron in the body is
sequestered in specialized cells (over 75% is found in Hb
inside the red cells), transport or storage proteins
(transferring or ferritin), in which iron is not redox active
and incapable of generating free radicals. It has been
suggested that redox active iron, rather than total body iron
status, is more likely to be associated with lipid peroxidationVascular Health and Risk Management 2005:1(1) 26
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and clinically manifested atherosclerosis (Shah and Alam
2003). Redox active serum iron may exist in many forms,
such as iron bound to albumin or citrate; iron bound to
glycosylated proteins, which have an increased affinity for
iron; or Hb-derived iron delocalized outside of the
hydrophobic heme pocket as occurs when Hb is oxidized
(Puppo and Halliwell 1988; Ferrali et al 1997).
We have demonstrated Hp type dependent differences
in the amount of serum redox active iron activity in the
diabetic condition both in vitro and in vivo. First, we have
shown a dramatic increase in the amount of chelatable redox
active iron associated with Hp2-2-Hb as compared with
Hp1-1-Hb complexes in vitro. Second, we have
demonstrated marked diabetes dependent differences in the
amount of redox active iron present in the plasma of mice
genetically modified to express the Hp2 allele as compared
with mice expressing the Hp1 allele (wild type). Finally,
we have shown that redox active iron is increased in the
plasma of humans with the Hp2-2 phenotype. These findings
provide further clues as to why diabetic individuals carrying
the Hp2-2 phenotype have an increased incidence of diabetic
vascular disease.
Future directions
An increase in oxidative stress has been proposed to be of
fundamental importance in the development of diabetic
microvascular and macrovascular complications (Nishikawa
et al 2000). We have proposed a new pathway for generation
of this oxidative stress involving Hp type dependent
differences in Hb-induced damage in the vessel wall in
diabetic patients. Based on this model, we suggest that
antioxidant therapy may be more beneficial in diabetic
patients with the Hp2-2 phenotype as compared with those
with the Hp1-1 phenotype. Several recent reports failed to
demonstrate any benefit from antioxidant supplementation
with vitamin E, alone or in combination with other
antioxidant vitamins, in reducing the incidence of major
adverse cardiovascular events in people with or without
diabetes (Yusuf et al 2000; MRC/BHF Heart Protection
Study 2002). The Heart Outcomes Prevention Study (HOPE)
trial was one such study that did not demonstrate any
cardiovascular benefit of daily administration of 400 IU of
vitamin E for 4.5 years in either the overall study population
and in study participants with diabetes. We were able to
determine the relative risk reduction associated with
vitamin E therapy according to Hp type in patients with and
without diabetes in all of the Canadian participants of the
HOPE study (3176 participants). We found that there was
no benefit of vitamin E supplementation detected in either
the entire group or in the diabetic subset. However, in
diabetic participants with Hp2-2, vitamin E supplementation
was associated with a statistically significant reduction in
cardiovascular death (relative risk 0.45, 95% confidence
interval (CI) 0.23–0.90) and non-fatal myocardial infarction
(relative risk 0.57, 95% CI 0.33–0.97). While clearly these
findings need to be confirmed prospectively, they may
suggest that antioxidant therapy with vitamin E may reduce
cardiovascular morbidity and mortality in diabetic patients
with Hp2-2. Moreover, we have demonstrated that redox
active iron is also increased in Hp2-2 diabetic individuals,
contributing to the increased oxidative stress in this
subgroup. As this redox active iron is chelatable, these
findings suggest that iron chelators may be beneficial in
reducing CVD in diabetic population with Hp2-2 phenotype.
If antioxidant supplementation, such as vitamin E or iron
chelators or a combination of both, is validated pro-
spectively, Hp phenotyping may become a useful tool to
identify diabetic individuals for whom antioxidant therapy
may be effective in reducing the incidence and severity
of CVD.
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